SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Surmodics, Inc. (SRDX) , 前瞻盈利收益率 0.65%.
本页证实的标准:
- VALUE (35/100, 未通过) — 综合估值评分低于60/100的通过门槛。
- 前瞻市盈率 153.5
- 分析师共识目标价 $39.50 (-8.1% 下行风险) — 轻微下行风险 — 市场可能已超前于分析师预期。
SharesGrow 综合评分： 40/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
35/100
Price-to-Earnings & upside
Proven by this page
~
健康
67/100
Debt-to-Equity & liquidity
→ Health
估值概览 — SRDX
估值倍数
P/E (TTM)0.0
前瞻 P/E153.5
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率4.82
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.82
前瞻 EPS（预估）$0.28
每股账面价值$0.00
每股营收$8.91
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield0.65%
股息收益率0.00%
分析师目标价$39.50 (-8.1%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2015 |
$1.01 |
$61.9M |
$13.45M |
21.7% |
| 2016 |
$0.76 |
$71.37M |
$9.99M |
14% |
| 2017 |
$0.29 |
$73.11M |
$3.93M |
5.4% |
| 2018 |
$-0.34 |
$81.34M |
$-4.46M |
-5.5% |
| 2019 |
$0.55 |
$100.08M |
$7.59M |
7.6% |
| 2020 |
$0.08 |
$94.86M |
$1.12M |
1.2% |
| 2021 |
$0.30 |
$105.14M |
$4.24M |
4% |
| 2022 |
$-1.96 |
$99.95M |
$-27.27M |
-27.3% |
| 2023 |
$-0.11 |
$132.58M |
$-1.54M |
-1.2% |
| 2024 |
$-0.82 |
$126.08M |
$-11.54M |
-9.2% |
